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–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Objective: Serine proteases are redundant enzymes implicated in the extracellular modulation
required for tumor growth and invasion. Tumor-associated diﬀerentially expressed gene-14
(TADG-14) is a novel transmembrane serine protease recently reported by our group to be highly
overexpressed in ovarian carcinomas. The goal of this study was to investigate the frequency of
expression of the TADG-14 gene in human cervical tumors.
Study design: TADG-14 expression was evaluated in 19 cervical cancer cell lines (11 primary and
8 established cell lines) as well as in 8 normal cervical keratinocyte cultures by reverse transcrip-
tase polymerase chain reaction. In addition, to validate gene expression data at the protein level,
TADG-14 expression was evaluated by immunohistochemistry on paraﬃn-embedded tissue from
which all 11 primary tumor cell lines were established.
Results: TADG-14 was found to be highly expressed in 82% (9/11) primary cervical cancer cell
lines and in 87% (7/8) established cervical cancer cell lines by reverse transcriptase-polymerase
chain reaction. Expression of TADG-14 by primary squamous cervical tumors was 100% (6/
6), whereas 60% (3/5) of primary adenocarcinomas expressed TADG-14. In contrast, none of
the normal cervical keratinocyte control cultures (n=4) or ﬂash frozen normal cervical biopsy
specimens (n=4) expressed TADG-14. Immunohistochemistry staining of parafﬁn-embedded
cervical cancer specimens conﬁrmed TADG-14 expression in tumor cells and its absence on nor-
mal cervical epithelial cells.
Conclusion: Cervical cancer expressed a high level of TADG-14, suggesting that this protease may
play an important role in invasion and metastasis. Because TADG-14 appears only in abundance
in tumor tissue and contains a secretion signal sequence, suggesting that TADG-14 is secreted, it
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–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––Tumor invasion and metastatic spread is a multistep
process that begins with the shedding of malignant cells
from the primary site, transporting the cells through
blood vessels, and seeding at distant organs, resulting
in tumor-associated metastasis.1-3 In the last few years,
strong clinical and experimental evidence has accumu-
lated that malignant cells depend on a group of proteo-
lytic enzymes synthesized and secreted by tumor cells
to disrupt basement membranes, invade neighboring
tissues, and metastasize.1-3 Consistent with this view,
several reports have demonstrated a positive correlation
between cancer progression and expression of extra-
cellular proteases such as matrix metalloproteinases
(MMPs) and serine proteases (urokinase-type plasmino-
gen activator [uPA]) in a variety of human tumors.1-4
Furthermore, inhibitors of these proteolytic enzymes
have been shown to interfere with the spread of cancer
in animal models.5 These ﬁndings have prompted efforts
to develop novel anticancer therapies directed against
the proteolytic cascade initiated by MMPs and serine
proteases and the various signaling pathways mediated
by these enzymes.
Serine proteases are a family of protein-degrading
enzymes that play crucial roles in numerous biologic
processes, including activation of complement, blood
coagulation, degradation of extracellular matrix compo-
nent, and activation of growth and angiogenic factors.4
All serine proteases contain conserved histidine, aspar-
tate, and serine residues that are necessary for enzymatic
activity and are either secreted enzymes or sequestered in
cytoplasmic storage organelles awaiting signal-regulated
disease.4 During the last few years, several novel trans-
membrane serine proteases have been cloned and re-
ported in humans including hepsin,6 tumor-associated
differentially expressed gene-12 (TADG-12),7 TADG-14
(KLK8/Neuropsin/Ovasin),8 TADG-15 (Matriptase),9
TADG-16 (Testisin),10 stratum corneum chymotryptic
enzyme,11 seprase,12 and protease M.13 Several of these
membrane-spanning proteases have been reported to
have cytoplasmic N-terminal domains, suggesting possi-
ble functions in intracellular signal transduction.4 Im-
portantly, in prostate cancer, the secreted nature and/or
high level of expression of the serine protease prostate-
speciﬁc antigen (PSA) allows for its detection at aber-
rant levels in patient serum, making PSA an important
tumor marker for the early diagnosis of this disease.14
In breast cancer, the serine protease uPA has also proven
to be a useful negative prognostic marker for disease
progression.15To assess the value of secreted proteases as markers
for tumor detection and targets for therapeutic interven-
tion, our group has recently developed a screening strat-
egy using redundant primers to the conserved catalytic
triad domain of the serine protease family. By using this
approach to display serine protease transcripts found in
abundance in gynecologic tumor tissues, with little or no
expression in normal tissues, we recently reported the
identiﬁcation and cloning of several transmembrane
serine proteases, including TADG-14, in ovarian can-
cer.7-9,13 In this study we have evaluated the extent
and frequency of expression of the TADG-14 gene in
several primary and established squamous and adeno-
carcinoma cervical cancer cell lines. We report, to our
knowledge for the ﬁrst time, expression of TADG-14
on the majority of cervical tumors evaluated. These ﬁnd-
ings may have important implications for the use of
TADG-14 protease as a diagnostic tool or as a molecular
target for cervical cancer therapy.
Material and methods
Primary and established cervical cancer cell lines
Nineteen cervical cancer cell lines (ie, 11 primary and 8
established) were evaluated for TADG-14 expression by
reverse transcriptase-polymerase chain reaction (RT-
PCR). Commercially available established cervical can-
cer cell lines (ie, CaSki, SiHa, MS-751, HT-3, C33a,
Me180, HeLa, and C4-I) were purchased from the
American Type Culture Collection (Manassas, Va).
Tumors derived from primary specimens were staged
according to the International Federation of Gynecol-
ogy and Obstetrics (FIGO) operative staging system.
Fresh tumor biopsy specimens from patients who had
frankly invasive stage IB-IIA cervical cancer diagnosed
were obtained at the time of surgery through the Gy-
necologic Oncology Division and the Pathology De-
partment, University of Arkansas Medical Sciences
(UAMS), under the approval of the Institutional Re-
view Board. Radical abdominal hysterectomy and
lymph node dissection for invasive cervical cancer were
performed in all patients but one. Eight normal kerati-
nocyte control samples (ie, four primary keratinocyte
cultures and four ﬂash frozen biopsy specimens) were
obtained from cervical biopsies of hysterectomy speci-
mens from women who had benign disease diagnosed
and a previous report of a normal cytologic evaluation.
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established according to previously reported standard
tissue culture techniques.16 We studied 11 primary cer-
vical cancer and 4 primary keratinocyte cell lines, some
of which had been cultured for 3 to 4 weeks and others
over a much longer period. Purity of fresh tumor cul-
tures was tested by morphology, immunochemistry
staining, and/or ﬂow cytometry with antibodies against
cytokeratins. Only cell lines containing more than 99%
tumor cells were evaluated. Because tissue digestion
and prolonged in vitro cell culture may potentially alter
antigen expression, four adjunctive normal cervical ker-
atinocyte biopsy specimens were also evaluated for
TADG-14 expression before enzymatic digestion and/
or in vitro culture (ie, snap frozen in liquid nitrogen im-
mediately after collection).
RNA isolation and complementary DNA synthesis
RNA isolation from different cell lines was performed
using TRIzol Reagent (Invitrogen, Carlsbad, Calif) ac-
cording to the manufacturer’s instructions. To verify in-
tegrity, 4 mg of RNA from each sample was run in 1%
agarose gel using 18S+28S ribosomal RNA (Sigma, St
Louis, Mo) as positive control. First-strand comple-
mentary DNA (cDNA) was synthesized by using 5 mg
of total RNA, 1! RT-PCR buffer, 5 mmol/L magne-
sium chloride, 1 mmol/L dNTPs, 2.5 mmol/L random
hexamers, 1 U/mL Rnase inhibitor, and 2.5 U/mL of
MulLV reverse transcriptase (Gene Amp RNA PCR
kit; Applied Biosystems, Foster City, Calif ) in a total
volume of 20 mL. RNA extracted from CaOV3 serous
papillary ovarian cancer cell line, previously reported
to express TADG-14,8 was used as a positive control.
PCRs
The PCR reaction mixture consisted of cDNA, 0.4
mmol/L of sense and antisense primers, 2.5 mmol/L
magnesium chloride, 0.2 mmol/L dNTPs, 0.025 U/mL
Taq polymerase (Gene Amp RNA PCR kit; Applied
Biosystems) with reaction buffer in a total volume of
50 mL. The target sequences were ampliﬁed in parallel
with b-tubulin gene.
Thirty cycles of PCR for speciﬁc target were per-
formed in a GeneAmp PCR System 2700 (Applied Bio-
systems). Each PCR cycle included 30 seconds of
denaturation at 95(C, 30 seconds of annealing at 67(C,
and 30 seconds of extension at 72(C. The sequences of
the TADG-14-speciﬁc primers that produce the 230-bp
product were as follows: 5#-ACAGTACGCCTGGGA-
GACCA-3# forward and 5#-CTGAGACGGTGCAAT-
TCTGG-3# reverse. The sequences of b-tubulin primers
that produce the 454-bp product were as follows: 5#-
CGCATCAACGTGTACTACAA-3# forward and 5#-
TACGAGCTGGTGGACTGAGA-3# reverse.Antibody production and immunohistochemistry
Polyclonal antibodies were generated by immunization
of New Zealand White rabbits with one of three poly-
lysine-linked multiple antigen peptides derived from
the amino acid sequence of TADG-14 as previously
reported.8 These sequences are KYTVRLGDHSLQ
(T14-1), GHECQPHSQPWQ (T14-2), and LDWIK-
KIIGSKG (T14-3). Formalin-ﬁxed, parafﬁn-embedded
tissue blocks from eight normal uterine cervices (ie, con-
trols) and 11 invasive cervical carcinomas of the uterus
(6 squamous carcinomas and 5 adenocarcinomas), from
which primary cell lines were established, were retrieved
from the surgical pathology ﬁles of the UAMS and eval-
uated for TADG-14 expression. Study blocks were
selected after histopathologic review. The most repre-
sentative hematoxylin and eosin-stained block sections
were used for each specimen. Immunohistochemical
staining was performed with a Vectastain Elite ABC
Kit (Vector Laboratories, Burlingame, Calif ). Brieﬂy,
formalin-ﬁxed and parafﬁn-embedded specimens were
routinely deparafﬁnized and processed by using micro-
wave heat treatment in 0.01 mol/L sodium citrate buffer
(pH 6.0). The specimens were incubated in methanol
with 0.3% hydrogen peroxide for 30 minutes at room
temperature and then incubated with normal goat serum
for 30 minutes. The samples were incubated with antie
TADG-14 peptide-derived polyclonal antibody for 1
hour at room temperature in a moisture chamber, fol-
lowed by incubation with biotinylated antirabbit immu-
noglobulin G (IgG) for 30 minutes, and then incubated
with ABC reagent (Vector Laboratories) for 30 minutes.
The ﬁnal products were visualized by using the AEC
substrate system (DAKO, Carpenteria, Calif ), and sec-
tions were counterstained with hematoxylin before
mounting. Negative controls were performed by using
normal serum instead of the primary antibody.
Statistical analysis
Data were analyzed with the two-tailed t test and the
Student t test for paired data. In all tests, the difference
was considered signiﬁcant when P values were less
than .05.
Results
TADG-14 expression in primary and established
cervical cancer cell lines
To characterize the frequency of expression of the
TADG-14 gene in cervical tumors, we used RT-PCR
with cDNA derived from primary and established squa-
mous and adenocarcinoma cervical cancer cell lines as
a template. Cultures of normal cervical keratinocytes
were used as controls. All primary tumors studied were
Cane’ et al 63Figure 1 TADG-14 expression by RT-PCR on primary squamous cell carcinoma (CVX-1-6), primary adenocarcinoma (ADX1-5), and
normal cervical keratinocyte primary cell lines. The reaction products were electrophoresed through a 2% agarose gel and stained with
ethidium bromide. The 454-bp band represents the b-tubulin product, and the 230-bp band represents the TADG-14 product. TADG-14
Figure 2 TADG-14 expression by RT-PCR on established cervical cancer cell lines and normal keratinocyte flash-frozen biopsy
specimens. The reaction products were electrophoresed through a 2% agarose gel and stained with ethidium bromide. The 454-bp bandoriginated from patients diagnosed with stage IB (90%)
or IIA (10%) cervical cancer (mean ageG SD=38G 8
years, range 26-50 years). Ten patients received surgery
and 1 patient received radiation therapy as primary
treatment. PCR primers that amplify a TADG-14e
speciﬁc 230-bp product were synthesized and used in
reactions. Primers that produce a speciﬁc 454-bp PCR
product for b-tubulin were also used as internal con-
trols. Of the 19 cervical carcinomas studied, 16 (84%)
were found to express TADG-14 by RT-PCR. Figure
1 shows an ethidium bromide-stained agarose gel with
the separated RT-PCR products for normal cervical
keratinocytes and primary cervical cancer cell lines,
whereas Figure 2 shows the RT-PCR results for the
established cervical cancer cell lines. Both are represen-
tative of the typical results observed. Flash-frozen sam-
ples or cultures of normal cervical keratinocytes did not
express TADG-14 (Figures 1 and 2). In contrast,
TADG-14 was found to be expressed in 82% (9/11) of
primary cervical cancer cell lines and in 87% (7/8) of es-
tablished cervical cancer cell lines (P!.001). For indi-
vidual histologic subtypes of primary tumors, TADG-
14 expression by primary squamous cervical tumors was
100% (6/6), whereas for adenocarcinomaswas 60% (3/5).
Immunohistochemistry staining
To determine whether TADG-14 expression detected by
RT-PCR in primary cervical cancer cell lines is the resultof a selection of a subpopulation of cancer cells present
in the original tumor or whether in vitro expansion con-
ditions may have modiﬁed gene expression, we per-
formed immunohistochemical analysis of TADG-14
protein expression on formalin-ﬁxed parafﬁn-embedded
tumor tissue from all primary tumors from which pri-
mary cell lines were derived. As shown in the Table,
immunohistochemical staining supported the data
obtained by RT-PCR. By using a TADG-14 peptide-
directed antibody (T14-1), we observed no signiﬁcant
staining with normal cervical keratinocytes samples
(Figure 3, A). In contrast, similar to ovarian tumor cells
(Figure 3, B), intense staining was associated with cervi-
cal tumor cells of both squamous cell and adenocarci-
noma histologic subtypes (Figure 3, C and D). For
squamous carcinoma, the antigen appears to be associ-
ated with tumor cells in the form of ﬁne cytoplasmic
granules. These granular structures may be intermedi-
ates in the pathway that ultimately leads to the secretion
of TADG-14. In adenocarcinoma samples (Figure 3, D),
TADG-14 showed diffuse cytoplasmic staining.
Comment
The biologic aggressiveness of neoplastic cells lies in
their ability to proliferate abnormally and to invade
normal host tissues. Malignancies use proteases to pro-
vide a variety of services that assist in the process of
tumor progression, including activation of growth and
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and metastasis. Consistent with this view, previous work
has shown signiﬁcant changes in matrix MMPs and
their endogenous inhibitors during cervical tumor pro-
gression.17,18 In the process of studying proteolytic
enzymes playing a key role in tumor metastatic pro-
cesses, we have recently identiﬁed overexpression of
TADG-14 (Table) as well as other serine proteases in a
high percentage of ovarian cancers.7-9,13 Because of the
paucity of information on serine protease expression in
cervical carcinomas, in this work we have analyzed the
expression of the novel serine protease TADG-14 in sev-
eral short-term primary cultures as well as established
cervical cancer cell lines. We chose this approach to
evaluate differential TADG-14 gene expression in highly
enriched populations of cervical tumor-derived epithe-
lial cells. We report for the ﬁrst time that TADG-14 is
expressed in 84% (16/19) of the cervical carcinomas
studied, whereas it is undetectable in normal cervical
keratinocytes. These data therefore support the view of
TADG-14 as a highly differentially expressed serine pro-
tease in cervical tumors when compared with normal
control cells (ie, cervical keratinocytes). Furthermore,
to validate gene expression data at the protein expres-
sion level, TADG-14 expression was evaluated by im-
munohistochemistry on parafﬁn-embedded tissue from
which all 11 primary tumor cell lines were established.
All primary uncultured tumor specimens, from which
TADG-14 expression was detected by RT-PCR, express
detectable TADG-14 by immunohistochemistry. These
data conﬁrm that TADG-14 protein expression is de-
tectable on TADG-14 RNA-positive cervical cancer
cells. Of interest, 100% of the primary squamous cervi-
cal carcinomas and 60% of the primary adenocarcino-
Table TADG-14 expression in squamous and adenocarci-
noma cervical cancers and normal keratinocytes by immuno-
histochemistry
Tissue type TADG-14 expression
CVX 1 +
CVX 2 +
CVX 3 +
CVX 4 +
CVX 5 +
CVX 6 +
ADX 1 +
ADX 2 +
ADX 3 +
ADX 4 
ADX 5 
KRT 1 
KRT 2 
KRT 3 
KRT 4 
CVX, Squamous cervical cancer; ADX, adenocarcinomas; KRT, normalmas tested expressed TADG-14. These data suggest
that both squamous cervical tumors and adenocarcino-
mas may commonly overexpress TADG-14. The value
of TADG-14 as a diagnostic or therapeutic target may
depend on differential expression between cancer and
dysplasia. However, no data are yet available on
TADG-14 expression by cervical intraepithelial lesions.
Of interest, among other known proteases, TADG-14
most closely resembles the mouse protease known as
neuropsin, which was originally cloned from mouse hip-
pocampus and, subsequently, implicated in neuronal
plasticity.19 If TADG-14 functions in a manner similar
to mouse neuropsin, it may be capable of restructuring
the three-dimensional architecture of a tumor, allowing
for the shedding of tumor cells or the invasion of normal
host tissues by degrading ﬁbronectin.20
Because in previous studies we were unable to detect
the TADG-14 transcript in any of 50 normal human tis-
sues studied, although after prolonged Northern blot ex-
posure, extremely low levels of TADG-14 were detected
in normal kidney, breast, and lung,8 our results suggest
that this gene is under the control of a promoter that is
most active in human tumors, including ovarian and
cervical tumors, and that it may be possible to exploit
this ﬁnding for diagnostic and/or therapeutic means.
Consistent with this view, immunohistochemical stain-
ing of ovarian8 and cervical tumors (this article) revealed
that TADG-14 is highly associated with tumor cells.
Furthermore, because TADG-14 expression has also
been reported in other types of cancer, including pros-
tate, breast, and colon, it may prove to be an important
Figure 3 Immunohistochemical analysis of TADG-14 expres-
sion in cervical tumors. Representative immunoreactivity of
TADG-14 in normal epithelial cells (A), ovarian serous papillary
carcinomas (positive control) (B), cervical squamous cell carci-
noma CVX-2 (C), and adenocarcinoma ADX-1 (D) (original
magnification,!300). Although no staining is observed in normal
cervical keratinocytes, in squamous cell carcinoma TADG-14
appears to be most highly expressed along the invasive front of the
Cane’ et al 65target for the inhibition of tumor progression in a variety
of human tumors.
Persistent or recurrent cervical cancer no longer ame-
nable to control with surgery or radiation therapy re-
mains a discouraging clinical entity with a 1-year
survival rate between 10% and 15%.21 However, in pa-
tients in whom recurrence is limited to the central pelvis,
and in patients who have not previously received radio-
therapy as primary or adjunctive treatment, cure is po-
tentially achievable with ultraradical (ie, exenterative)
surgery or radiation therapy, respectively. Because of
the tendency of cervical cancer to directly invade adja-
cent deep pelvic tissues and spread by lymphatics, accu-
rate assessment of disease status remains problematic.
This is especially true in previously irradiated patients,
in whom the distinction between radiation ﬁbrosis and
disease recurrence may be extremely difﬁcult. A serum
tumor marker that accurately reﬂects the active tumor
status of the majority of patients with cervical cancer
would be particularly useful in this setting. Because
TADG-14 appears only in abundance in tumor tissue
and TADG-14 contains a secretion signal sequence
and immunohistochemical data suggest that TADG-14
is secreted,8,22 we speculate that this protease may prove
to be a useful tool for the early detection of recurrent/
persistent cervical cancer. Consistent with this view,
PSA has already been validated as a tumor marker for
the early diagnosis of prostate cancer because of its ab-
normal prevalence in the peripheral blood of patients.14
To validate this hypothesis, an enzyme-linked immuno-
sorbent assay detection kit for quantiﬁcation of TADG-
14 in the circulation of ovarian and cervical cancer
patients is under development in our laboratory. Future
studies, however, will be necessary to evaluate the poten-
tial of TADG-14 as a novel tumor marker in cervical
cancer.
The recognition of tumor antigen-loaded dendritic
cells (DCs) as one of the most promising approaches
to induce a tumor-speciﬁc immune response in vivo
has recently generated widespread interest in the use of
these ‘‘natural adjuvants’’ for the therapy of several hu-
man malignancies refractory to standard treatment mo-
dalities.23 The identiﬁcation and cloning of a group of
preferentially expressed serine proteases, including
TADG-14 as novel tumor-associated antigens, may
therefore offer the opportunity to use these targets to as-
sess the potential for therapeutic DC vaccination for the
treatment of human cancer patients refractory to stan-
dard treatment modalities.24 In agreement with this
view, our laboratory has recently identiﬁed cytotoxic T
lymphocyte epitopes against other serine proteases, in-
cluding hepsin and stratum corneum chymotryptic en-
zyme, that are highly differentially expressed genes in
ovarian carcinomas and pancreatic cancer.24 These data,
combined with the recently reported immunodominant
role played by the serine protease PSA in the prostatecancer-speciﬁc immune response induced by DCs trans-
fected with ampliﬁed tumor RNA25 or loaded with
killed prostate cancer cells,26 further suggest that pep-
tide epitopes derived from TADG-14 may become
selective targets for DC-driven CD8+ cytotoxic T lym-
phocyte against cervical cancer.
In conclusion, we have shown that primary and es-
tablished cervical cancer cell lines, but not normal cervi-
cal epithelial cells, frequently overexpress the TADG-14
gene, and we have further demonstrated that cervical tu-
mors expressed this transmembrane serine protease. On
the basis of these ﬁndings, we suggest that TADG-14
has the potential to become a useful diagnostic tool
for monitoring response to therapy as well as to detect
early recurrence after treatment and may also serve as
a novel target antigen for the therapy of cervical tumors
refractory to standard treatment modalities.
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